Quarterly report pursuant to Section 13 or 15(d)

Note 5 - Stock Incentive Plan (Details Textual)

v3.23.2
Note 5 - Stock Incentive Plan (Details Textual) - USD ($)
 3 Months Ended 6 Months Ended
Mar. 31, 2022
Apr. 30, 2020
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Oct. 31, 2017
Apr. 30, 2016
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) [1]         508,902      
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value     $ 300,000   $ 300,000      
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price (in dollars per share)     $ 4.01   $ 4.01      
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Outstanding, Weighted Average Exercise Price (in dollars per share)     4.33   4.33      
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expected to Vest, Outstanding, Weighted Average Exercise Price (in dollars per share)     $ 3.44   $ 3.44      
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount     $ 3,600,000   $ 3,600,000      
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)         2 years 9 months 18 days      
Share-Based Payment Arrangement, Expense, Tax Benefit     0 $ 0 $ 0 $ 0    
General and Administrative Expense [Member]                
Share-Based Payment Arrangement, Expense     256,297 204,692 500,634 409,166    
Research and Development Expense [Member]                
Share-Based Payment Arrangement, Expense     $ 216,999 $ 152,602 $ 448,871 $ 447,939    
Monopar Therapeutics Inc. 2016 Stock Incentive Plan [Member]                
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares) 5,100,000 3,100,000         1,600,000 700,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares) 2,000,000 1,500,000            
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)     0   508,902      
Monopar Therapeutics Inc. 2016 Stock Incentive Plan [Member] | Vesting 6/48ths on Six-months and 1/48th After [Member]                
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)         443,182      
Monopar Therapeutics Inc. 2016 Stock Incentive Plan [Member] | Vesting Quarterly Over One Year [Member]                
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)         55,720      
Monopar Therapeutics Inc. 2016 Stock Incentive Plan [Member] | Vesting Monthly Over One Year [Member]                
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)         10,000      
Monopar Therapeutics Inc. 2016 Stock Incentive Plan [Member] | Share-Based Payment Arrangement, Option [Member]                
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)         10 years      
[1] 508,902 options vest as follows: options to purchase 443,182 shares of the Company’s common stock vest 6/48ths on the six-month anniversary of grant date and 1/48th per month thereafter; options to purchase 55,720 shares of the Company’s common stock vest quarterly over one year; and options to purchase 10,000 shares of the Company’s common stock vest monthly over one year.